203
Views
7
CrossRef citations to date
0
Altmetric
Reports

Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells

, , &
Pages 489-495 | Received 19 Nov 2015, Accepted 03 Sep 2016, Published online: 21 Oct 2016
 

ABSTRACT

Glioblastoma is the most malignant primary brain tumor with a median survival of 15 months. Temozolomide (TMZ) is the standard of care for these patients. Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas. In the present study, we found that combination treatment in glioma cells with TMZ and DFP significantly reduced cell viability, produced cell cycle arrest at G2/M phase, and enhanced apoptosis. TMZ and DFP might be a potent new combination treatment for glioblastoma.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

This work was supported by a grant from the Joseph and Esther Gani Foundation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.